Core Viewpoint - Titanium Chemical (002145) is actively engaging in financial management and risk mitigation strategies, including the use of self-owned funds for wealth management and foreign exchange hedging, while also planning to renew its auditing firm and establish a compensation assessment method for executives [2][4][9]. Group 1: Financial Management - The company plans to use no more than 2 billion RMB of its own funds to purchase safe and liquid financial institution wealth management products, with a rolling usage period of 12 months from the date of shareholder meeting approval [2][8]. - The company intends to conduct foreign exchange hedging activities with a cumulative amount not exceeding 5 billion RMB and a maximum outstanding amount of 3 billion RMB, aimed at mitigating exchange rate fluctuation risks [5][8]. Group 2: Corporate Governance - The company will hold its sixth extraordinary shareholders' meeting on December 2, 2025, to discuss several key proposals, including the use of self-owned funds for wealth management and foreign exchange hedging [3]. - The company has proposed to renew the appointment of Lixin Certified Public Accountants as the auditing firm for the 2025 fiscal year, with audit fees set at 1.35 million RMB for financial statements and 200,000 RMB for internal control audits [4][8]. Group 3: Executive Compensation - The company has established a compensation assessment method for directors and senior management for 2026, with the chairman and president's base salary set at 1 million RMB, and independent directors receiving an annual allowance of 84,000 RMB [9].

Meeting Overview - The sixth session of the Supervisory Board of Tianrun Industrial Technology Co., Ltd. was held on August 21, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Financial Reporting - The Supervisory Board reviewed the 2025 semi-annual report and its summary, concluding that the report accurately reflects the company's actual situation without any false records or misleading statements [1][2]. Profit Distribution Plan - The profit distribution plan for the first half of 2025 was deemed compliant with the China Securities Regulatory Commission's guidelines and the company's articles of association, considering both shareholder returns and future business development [2][3]. Investment in Financial Products - The Supervisory Board approved the use of idle funds to purchase bank financial products, which is expected to enhance the efficiency of fund utilization and increase company revenue without harming the interests of shareholders, especially minority shareholders [3]. Related Party Transactions - The anticipated increase in related party transaction limits for 2025 was approved, aligning with the company's operational needs and adhering to fair market pricing, ensuring no harm to the company's independence or shareholder interests [3].

Group 1 - The company held its sixth meeting of the second supervisory board on June 3, 2025, with all three supervisors present, and the meeting was deemed legally valid [1] - The supervisory board approved the 2024 annual work report and the financial settlement report, which indicated a net profit of CNY 110,969,670.87 for 2024 and undistributed profits of CNY 203,428,848.19 [2] - The proposed profit distribution plan includes a cash dividend of CNY 1.50 per 10 shares, amounting to a total of CNY 14,060,934.00, based on the total share capital of 93,739,560 shares as of June 3, 2025 [2] Group 2 - The supervisory board agreed to renew the appointment of Zhonghui Certified Public Accountants for the 2025 audit, citing their adherence to independent auditing principles [4] - The company plans to apply for bank credit facilities not exceeding CNY 300 million to support its operational and business development needs, with the ability to adjust the guarantee amount among subsidiaries [5][6] - The company intends to engage in foreign exchange derivative transactions with a maximum amount of CNY 30 million to manage foreign currency risks effectively [6] Group 3 - The company plans to invest up to CNY 10 million of temporarily idle funds in low-risk financial products with high liquidity and short-term maturity [7] - The company will revise its articles of association in accordance with relevant laws and regulations, with the proposal requiring approval at the 2024 annual shareholders' meeting [7]

Core Viewpoint - The company reported a decline in revenue and net profit for the year 2024, primarily due to falling prices of pesticide products, despite an increase in production and sales volume [18]. Group 1: Company Overview - The company, Haier Pharmaceutical Group Co., Ltd., is engaged in the research, production, and sales of pesticide formulations, intermediates, and raw materials, with a focus on insecticides and fungicides [4][15]. - The pesticide industry is characterized by relatively inelastic demand, playing a crucial role in agricultural production and food security [2][3]. Group 2: Financial Performance - The company achieved operating revenue of CNY 3.91 billion in 2024, a decrease of 11.16% from CNY 4.40 billion in 2023 [18]. - The net profit attributable to shareholders was CNY 181.37 million, down 61.67% from CNY 473.20 million in the previous year [18]. - The net cash flow from operating activities was CNY 285.55 million, a significant decrease of 70.11% compared to CNY 955.35 million in 2023 [18]. Group 3: Market Dynamics - The global demand for pesticides is expected to grow due to increasing food security needs and agricultural efficiency [2]. - China's pesticide production capacity is shifting towards countries like China and India, driven by the expiration of patents and restructuring by multinational agrochemical giants [2][3]. Group 4: Product Development - The company has been diversifying its pesticide offerings, with several new products entering trial production in recent years, including various insecticides and fungicides [4][5]. - The company is focusing on high-efficiency, low-toxicity pesticides to meet the growing market demand [2][4]. Group 5: Industry Trends - The pesticide industry is experiencing a shift towards biopesticides and environmentally friendly products, with increasing market share for biological and chemical pesticides [7]. - The market for generic pesticides is expected to expand as patents expire, providing opportunities for companies with strong R&D capabilities [2][3].

证券代码：600782 证券简称：新钢股份 公告编号：临2025-008 新余钢铁股份有限公司 第十届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 2025 年 2 月 26 日，新余钢铁股份有限公司（以下简称"公司"）第 十届董事会第六次会议在公司会议室召开，本次会议通知及会议材料以电 子邮件方式送达，会议以现场结合视频方式召开。会议由公司董事长刘建 荣先生主持，会议应参加表决董事 8 人，实际参加表决董事 8 人；公司监 事会成员及部分高级管理人员列席会议。会议的召集和召开方式符合有关 法律法规和《公司章程》的有关规定。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 （二）审议通过《关于公司 2024年度日常性关联交易执行情况暨 2025 年度关联交易预计情况的议案》 同意公司与关联方进行的日常性关联交易事项，同意将本议案提交公 司股东大会审议，并提请股东大会授权公司管理层根据业务开展需要，在 预计的年度日常关联交易范围内，签订有关协议及合同。 关联董事刘建荣、刘 ...